Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHST vs CVAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVAC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

CVAC Overall Winner 6-Pillar Tally: BHST 1 – 4 CVAC (1 Tie) Matrix Metrics: BHST 1 – 9 CVAC

As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin).

  • Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BHST 58.2/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHST vs CVAC
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58
CVAC NASDAQ Head-to-Head Winner
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap $1.1B
TTM Revenue $71M
Forward P/E 5.2x
Beta / 30D Vol 1.20β · 62% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $4.64 · SMA50: $5.02

6-Pillar Scorecard Institutional Category Breakdown (BHST 1 – 4 CVAC)

Columns: Metric · BHST · CVAC
1. Valuation Multiples CVAC
Forward P/E N/M 5.2x
Trailing P/E N/M 7.0x
PEG Ratio N/M N/M
EV / Revenue 0.7x 14.9x
2. Growth & Scale CVAC
Revenue Growth (YoY) +3.8% -89.0%
Earnings Growth (YoY) +0.0% +24.0%
TTM Revenue (USD) $35M $71M
Market Cap $29.9M $1.1B
3. Profitability & Quality CVAC
Gross Margin 59.0% 93.3%
Operating Margin -18.0% 573.0%
Net Profit Margin -31.2% 182.1%
Return on Equity (ROE) -142.5% 40.2%
4. Balance Sheet & Cash Flow CVAC
Cash Generation (TTM) -$9.4M $194M EBITDA
Cash Flow Margin -26.6% N/A
Net Cash / Leverage $5.1M Net Cash $5.65 Book/Sh · 40.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 63.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 77.0% of Rev ($27M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHST (1) vs CVAC (9)
Institutional Metric BHST CVAC Criterion Row Edge
Market Capitalization
Scale
$29.9M $1.1B Larger Scale CVAC
Trailing P/E Ratio
Valuation
N/M 7.0x Lower Multiple CVAC
Forward P/E Ratio
Valuation
N/M 5.2x Lower Multiple CVAC
Revenue Growth (YoY)
Growth
+3.8% -89.0% Higher Growth BHST
Operating Margin (TTM)
Profitability
-18.0% 573.0% Higher Margin CVAC
Net Profit Margin
Profitability
-31.2% 182.1% Higher Margin CVAC
Return on Equity (ROE)
Capital Efficiency
-142.5% 40.2% Higher ROE CVAC
52-Week Range Position
Momentum
6% ($1–$7) 67% ($2–$6) Stronger Trend CVAC
Beta / 30D Volatility
Risk Regime
0.25β · 86% Vol 1.20β · 62% Vol Lower Realized Risk CVAC
Unified Institutional Score
Composite Signal
58.2 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite CVAC
Trailing 12M Revenue (USD)
Operating Scale
$35M $71M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.0% 93.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 14.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M ($5.1M Net Cash) $194M EBITDA ($5.65 Book/Sh · 40.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVAC +7.45 pp
BHST: -17.4% · CVAC: -9.95%
3M Horizon CVAC +3.53 pp
BHST: -14.26% · CVAC: -10.73%
6M Horizon CVAC +3.53 pp
BHST: -14.26% · CVAC: -10.73%
1Y Horizon CVAC +3.53 pp
BHST: -14.26% · CVAC: -10.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs CVAC. Trailing 12-month operating profitability (BHST -18.0% vs CVAC 573.0%) and valuation multiples (BHST N/M vs CVAC 5.2x Forward P/E) are benchmarked directly in Pillar 4 below.

BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M
CVAC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross Margin93.3%
Op. Margin573.0%
ROE / Fwd P/E40.2% · 5.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 63.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published
CVAC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 573.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHST vs CVAC Key Questions & Quantitative Answers

As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin). Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BHST 58.2/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVAC leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with CVAC at -89.0% YoY revenue growth and +24.0% YoY earnings growth on $71M TTM revenue (93.3% gross margin, 573.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus $71M for CVAC. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVAC.

CVAC screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas CVAC trades at 5.2x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus CVAC (40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, CVAC carries 63.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.